YAP1 and hepatocellular carcinoma: Furthermore, other crucial targets and their regulatory loops representing potential therapeutic options for HCC have been reported, including Phospholipase 1 inhibited by T-box transcription factor 3 (TBX3), YAP-dependent monocyte chemoattractant protein 1 (MCP-1) in a protumoral microenvironment, Meis homeobox 2C/D (MEIS2C/D) activating Wnt/β-catenin and inhibiting Hippo pathway, and the YAP/nuclear receptor 4A1 (NR4A1) (66–69) (Table 1).